Conditions: Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; Thyroid Gland Medullary Carcinoma
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: National Cancer Institute (NCI)
Active, not **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
